K2M Group Holdings Inc  

(Public, NASDAQ:KTWO)   Watch this stock  
Find more results for K2M, Inc
-0.39 (-3.00%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.31 - 12.89
52 week 12.31 - 26.29
Open 12.89
Vol / Avg. 122,480.00/195,354.00
Mkt cap 503.47M
P/E     -
Div/yield     -
EPS -1.07
Shares 41.23M
Beta     -
Inst. own 66%
Mar 16, 2016
Q4 2015 K2M Group Holdings Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jan 11, 2016
Preliminary 2015 K2M Group Holdings Inc Earnings Release
Dec 3, 2015
K2M Group Holdings Inc at Evercore ISI Medtools & Outsourcing Investor Forum
Dec 1, 2015
K2M Group Holdings Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -18.57% -31.95%
Operating margin -18.20% -25.70%
EBITD margin - -7.85%
Return on average assets -12.23% -19.89%
Return on average equity -14.33% -29.92%
Employees 448 -
CDP Score - -


751 Miller Dr SE
LEESBURG, VA 20175-8993
United States - Map
+1-703-7773155 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


K2M Group Holdings, Inc. (KTWO) is a global medical device company focused on designing, developing and commercializing spine technologies and techniques. The Company's spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. The Company is engaged in the design, development and commercialization of a number of minimally invasive spine (MIS) products and products for patients suffering from degenerative spinal conditions. The Company's products consist of implants, disposables and instruments, which are marketed and sold primarily to hospitals for use by spine surgeons. The Company's technologies include MESA, Rail 4D, Deformity Cricket, CAPRI, SERENGETI, RAVINE, EVEREST and tifix. The Company offers products-based on its technologies for complex spine, minimally invasive spine and degenerative spine. The Company is engaged in product development activities for the spine and MIS markets.

Officers and directors

Daniel A. Pelak Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Eric D. Major President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Gregory S. Cole CPA Chief Financial Officer
Age: 44
Bio & Compensation  - Reuters
George Z. Moratis Global Accounting Officer (Principal Accounting Officer)
Age: 47
Bio & Compensation  - Reuters
Kostuik P. John Chief Medical Officer, Director
Age: 77
Bio & Compensation  - Reuters
Brett P. Brodnax Director
Age: 50
Bio & Compensation  - Reuters
Carlos A. Ferrer Director
Age: 57
Bio & Compensation  - Reuters
Paul B. Queally Director
Age: 50
Bio & Compensation  - Reuters
Sean M. Traynor Director
Age: 46
Bio & Compensation  - Reuters
Michael A Turpin Director
Age: 53
Bio & Compensation  - Reuters